SCHEMBL4829499

SCHEMBL4829499

O=C(Cc1ccccc1)c1c[nH]c2ncccc12

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.61
MAP2K1 Q02750 1/20 0.57
CCNE1 P24864 6/20 0.56
CDK2 P24941 6/20 0.56
MET P08581 1/20 0.55
PKM P14618 1/20 0.53
LATS1 O95835 1/20 0.52
LATS2 Q9NRM7 1/20 0.52
ROCK1 Q13464 1/20 0.51
HAT1 O14929 1/20 0.48
EP300 Q09472 1/20 0.48
MTNR1A P48039 1/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
CNR2 P34972 1/20 0.47
CAMKK2 Q96RR4 1/20 0.47
KDR P35968 1/20 0.47
GPR84 Q9NQS5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831662 0.84 MAP2K1 (0.56) ADORA2AMAP2K1CCNE1CDK2PKM
SCHEMBL3886913 0.82 MAP2K1 (0.63) ADORA2AMAP2K1CCNE1CDK2PKM
SCHEMBL29468201 0.81 MAP2K1 (0.71) ADORA2AMAP2K1CCNE1CDK2MET
SCHEMBL985214 0.81 MAP2K1 (0.71) ADORA2AMAP2K1CCNE1CDK2MET
SCHEMBL13306576 0.81 MAP2K1 (0.61) ADORA2AMAP2K1CCNE1CDK2PKM
SCHEMBL13333283 0.81 MAP2K1 (0.61) ADORA2AMAP2K1CCNE1CDK2PKM
SCHEMBL4466016 0.81 MAP2K1 (0.61) ADORA2AMAP2K1CCNE1CDK2PKM
SCHEMBL12729266 0.81 MAP2K1 (0.66) ADORA2AMAP2K1CCNE1CDK2PKM
Hydrochloric Acid SCHEMBL3608101 0.80 MAP2K1 (0.69) ADORA2AMAP2K1CCNE1CDK2MET
SCHEMBL857192 0.79 MAP2K1 (0.52) ADORA2AMAP2K1CCNE1CDK2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
EP-1664043-A2 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2006-06-07 EP disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed
WO-2005028475-A2 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-03-31 WO disclosed
WO-2005028475-A2 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 ADORA2A 3635/4885MAP2K1 403/4885CCNE1 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.